Pooled analysis shows moderate/severe exacerbation rate reduction with astegolimab in COPD

ORLANDO — Adults with COPD and frequent exacerbations had a significantly lower yearly moderate/severe exacerbation rate with astegolimab vs. placebo, according to data presented at the American Thoracic Society International Conference.These findings on astegolimab (Genentech, Roche), described as “a human [immunoglobulin]G2 monoclonal antibody that blocks ST2-mediated